Cardiovascular disease Archives

News and Trends 3 Jun 2015

Poor topline results for NeuroVive’s CicloMulsion Phase III

Phase III is a critical step in a drug development process. NeuroVive Pharmaceutical has learned this the hard way. The Swedish company reported unsatisfactory results of CicloMulsion’s phase III clinical trial in patients having gone through a specific type of heart attack known as STEMI (ST-segment elevation acute myocardial infarction). The disappointing topline results are expected to […]

June 3, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 27 May 2015

NewCo, the union of Sorin and Cyberonics

[UPDATE 27/05/2015]: Sorin’ shareholders approved the merger with Cyberonics in an Extraordinary Meeting. Sorin and Cyberonics, agreed on a merger plan to create a new global leader in medical technologies with a combined equity value of approximately €2.4Bn based on the closing price of Sorin and Cyberonics shares of 25th February. Sorin and Cyberonics will combine […]

May 27, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 15 Apr 2015

Heart Metabolics bargain with the FDA for a single Phase III

Heart Metabolics received an agreement letter from the FDA related to the company’s proposed phase III trial Special Protocol Assessment (SPA) request. The FDA has agreed to a single, randomized, pivotal Phase III trial of 350 patients evaluating perhexiline for the treatment of moderate-to-severe hypertrophic cardiomyopathy (HCM). The company, focused on the development of drugs […]

April 15, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 11 Apr 2015

Cardio3 Biosciences Embedded BioLife Solutions for a Heart Regenerative Therapy

Cardio3 BioSciences is again on the front page of biotech news. After announcing the launching of an IPO on Nasdaq and getting an US patent, the company has now embedded the BioLife Solutions‘ clinical grade CryoStor cryopreservation freeze media, in its ongoing Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) phase III clinical trial in Europe and Israel and the pending CHART-2 phase III clinical trial […]

April 11, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 7 Apr 2015

A New Key Strategic Collaboration Between BMS and UniQure

Last month, Bristol-Myers Squibb (BMS) and UniQure, the Dutch pioneer in human gene therapy, were at the forefront of the scene after having agreed on two collaborations, respectively, an agreement between Bavarian Nordic & BMS and a collaboration between Sympromics & UniQure. A few days ago, they announced an exclusive strategic collaboration to develop gene therapies for cardiovascular […]

April 7, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 2 Apr 2015

Interview with CELLPROTHERA, the regenerative medicine pioneer

CellProthera is a medical biotech company founded in 2008 in Mulhouse, France. The young innovative company focuses on the use of blood peripheral stem cells. CellProthera is the origin of a revolutionary therapy allowing the regeneration of myocardial tissue following acute myocardial infarct (AMI) by injection of a cell graft containing autologous adult stem cells […]

April 2, 2015 - 7 minutesmins - By Nicolas Sainte-Foie

News and Trends 12 Feb 2015

Neurostimulation, an Innovative Approach to Treat Heart Failure

The revolutionary Equilia system, meant to treat heart failure, has been successfully implanted for the first time in a clinical study . The developer of the system, Sorin Group, is an Italian medical device company, leader in the treatment of cardiovascular diseases. Heart failure is a chronic progressive disease in which the heart can no longer […]

February 12, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 Oct 2014

A Hydrogel to treat Advanced Heart Failure in Europe

LoneStar Heart, Inc. announced that it received the CE Mark (European Conformity) for its Algisyl-LVR® hydrogel implant,a product for the treatment of advanced heart failure (HF). The CE Mark indicates a product’s compliance with European Union legislation and that it can be sold throughout the European Economic Area. Classified in Europe and in the U.S. as a medical device, Algisyl-LVR is […]

October 4, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 3 Sep 2014

EMA give Orphan Drug Designation to the CER-001 of Cerenis

Cerenis Therapeutics, the biopharmaceutical company developing CER-001, an engineered human apoA-I-containing pre-beta HDL mimetic, for the treatment of cardiovascular disease, announced today that it has received two separate Orphan Drug Designations from the European Medicines Agency (EMA) for the use of CER-001 in the treatment of patients with rare genetic defects in HDL synthesis/maturation pathways, […]

September 3, 2014 - 3 minutesmins - By Joachim Eeckhout

News and Trends 31 Aug 2014

Why should you drink tea instead of coffee?

Drinking tea reduces non-cardiovascular mortality by 24%, reveals a study in 131 000 people presented at ESC Congress today by Professor Nicolas Danchin from France. Professor Danchin said: “If you have to choose between tea or coffee it’s probably better to drink tea. Coffee and tea are important components of our way of life. Their […]

August 31, 2014 - 4 minutesmins - By Julie Lellouche

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cardiovascular disease

Poor topline results for NeuroVive’s CicloMulsion Phase III

NewCo, the union of Sorin and Cyberonics

Heart Metabolics bargain with the FDA for a single Phase III

Cardio3 Biosciences Embedded BioLife Solutions for a Heart Regenerative Therapy

A New Key Strategic Collaboration Between BMS and UniQure

Interview with CELLPROTHERA, the regenerative medicine pioneer

Neurostimulation, an Innovative Approach to Treat Heart Failure

A Hydrogel to treat Advanced Heart Failure in Europe

EMA give Orphan Drug Designation to the CER-001 of Cerenis

Why should you drink tea instead of coffee?

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!